Introduction
Growth hormone secretagogues (GHS) are a class of peptides that stimulate the release of growth hormone (GH) from the anterior pituitary gland. They represent a major area of research interest in endocrinology, metabolic science, and ageing biology. Browse our full range of Muscle Growth & Performance peptides.
For research and laboratory use only. Not intended for human or veterinary administration.
The GH Axis
Growth hormone release is regulated by two primary hypothalamic hormones: GHRH, which stimulates GH secretion, and somatostatin, which inhibits it. GH secretagogues act either by mimicking GHRH, by activating the ghrelin receptor (GHS-R1a), or both simultaneously.
GHRH Analogues
Sermorelin
A synthetic analogue of the first 29 amino acids of endogenous GHRH. Binds to the GHRH receptor on pituitary somatotrophs, stimulating GH synthesis and release in a physiological, pulsatile manner. Used in research into pituitary function, GH deficiency models, and age-related GH decline.
CJC-1295 (No DAC)
CJC-1295 (No DAC) is a modified GHRH analogue with a half-life of ~30 minutes. Produces a more physiological GH pulse. Commonly studied in combination with GHRP peptides for synergistic GH release. Also available as a pre-combined CJC-1295 (No DAC) + Ipamorelin blend.
CJC-1295 (With DAC)
CJC-1295 (With DAC) — the DAC modification enables albumin binding, extending half-life to ~6–8 days. Produces sustained GH elevation rather than pulsatile release — useful for research into chronic GH stimulation models.
Tesamorelin
A stabilised GHRH analogue studied extensively in visceral adiposity and lipodystrophy models. Research has also explored effects on cognitive function and IGF-1 levels.
Ghrelin Receptor Agonists (GHRPs)
GHRP-2
A potent agonist at the GHS-R1a (ghrelin receptor). Produces strong GH release and has been studied for effects on appetite regulation, GH axis function, and cardioprotection in preclinical models.
GHRP-6
GHRP-6 has a similar mechanism to GHRP-2 but with a more pronounced appetite-stimulating effect via hypothalamic NPY neurons. Used in research models of cachexia, GH deficiency, and gastric motility.
Hexarelin
One of the most potent synthetic GHRPs. Studied for GH-releasing properties as well as direct cardioprotective effects mediated through CD36 receptor binding, independent of GH release.
Ipamorelin
Ipamorelin is a highly selective GHS-R1a agonist with minimal effect on cortisol or prolactin — preferred for research requiring clean GH stimulation without confounding hormonal effects. Often combined with CJC-1295 (No DAC).
Combined Research Protocols
A common approach combines a GHRH analogue (e.g. CJC-1295 No DAC) with a GHRP (e.g. Ipamorelin) to exploit synergistic GH release. The two classes act on different receptors and their combined effect is significantly greater than either alone. The CJC-1295 (No DAC) + Ipamorelin blend is available for combined administration studies.
MK-677 (Ibutamoren)
A non-peptide GHS-R1a agonist with oral bioavailability. Produces sustained GH and IGF-1 elevation. Used in research models of muscle wasting, bone density, sleep architecture, and metabolic function.
Storage and Handling
Store lyophilised GH peptides at −20°C. Reconstitute with bacteriostatic water. Once reconstituted, store at 2–8°C and use within 28 days. Avoid agitation and repeated freeze-thaw cycles.
All products supplied by Vanta Labs are intended strictly for laboratory and research purposes.